News 2025-11-18
Porton Improves in the 2025 S&P Global ESG Score
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 50 in the 2025 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved (ESG Score as of 12/11/2025).
In this year’s assessment, Porton’s scores in Environmental, Social and Governance & Economic dimensions increase by 12, 5, and 3 points respectively. Notable progress was made in criteria such as Energy, Waste & Pollutants, Water, Climate Strategy, and Supply Chain Management.
Adhering to the ESG concepts of "Green Development, Promote Common Progress, build a Healthy Society, and Enhance Corporate Governance", Porton is committed to integrating ESG into its corporate strategy and operations, and continuously strengthens the management of material issues.
In 2025, Porton further enhanced its ESG management through various measures. At the commitment level, our carbon reduction target has been verified by the SBTi, and we also released environmental targets covering three major areas of energy, water resources and waste management. At the management system level, we formulated Supplier Code of Conduct to further promote supply chain management. At the personnel capability level, we organized trainings on carbon verification and sustainable supply chain to improve employees’ professional skills.
Looking ahead, Porton will continue to practice the ESG development concept and promote sustainable development.
Others
More
News 2026-09-01
Porton to Showcase End-to-End CDMO Expertise at CPHI Milan 2026
CPHI creates connections and inspires partnerships across the global pharma community, championing innovation at the heart of pharma through in-person and online events that grant access to endless opportunities.

News 2026-08-05
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.